These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8491007)

  • 41. HTUPA as a new thrombolytic agent for acute myocardial infarction: a multicenter, randomized study.
    Sun Y; Liu X; Guo L; Pang W; Guo X; Sun Z; Li Z; Cui X; Li H; Tao G; Wang L; Zhou C; Liu Y; Shan H; Wang M; Liu M; Li J; Yin L; Hu D
    Int J Cardiol; 2014 Mar; 172(2):326-31. PubMed ID: 24525155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study.
    Williams MJ; Morison IM; Parker JH; Stewart RA
    J Am Coll Cardiol; 1997 Aug; 30(2):364-9. PubMed ID: 9247506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction.
    O'Neill WW; Weintraub R; Grines CL; Meany TB; Brodie BR; Friedman HZ; Ramos RG; Gangadharan V; Levin RN; Choksi N
    Circulation; 1992 Dec; 86(6):1710-7. PubMed ID: 1451242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
    Bruna C; Rossetti G; Vado A; Racca E; Steffenino G; Dellavalle A; Ribichini F; Ferrero V; Menardi E; Uslenghi E
    G Ital Cardiol; 1998 Jan; 28(1):3-11. PubMed ID: 9493040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
    Ross AM; Molhoek P; Lundergan C; Knudtson M; Draoui Y; Regalado L; Le Louer V; Bigonzi F; Schwartz W; de Jong E; Coyne K;
    Circulation; 2001 Aug; 104(6):648-52. PubMed ID: 11489769
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
    Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
    Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Restenosis after delayed coronary angioplasty of the culprit vessel in patients with a recent myocardial infarction treated by thrombolysis.
    Bauters C; Khanoyan P; McFadden EP; Quandalle P; Lablanche JM; Bertrand ME
    Circulation; 1995 Mar; 91(5):1410-8. PubMed ID: 7867181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction.
    Wilson SH; Bell MR; Rihal CS; Bailey KR; Holmes DR; Berger PB
    Am Heart J; 2001 May; 141(5):704-10. PubMed ID: 11320356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience.
    Lesnefsky EJ; Lundergan CF; Hodgson JM; Nair R; Reiner JS; Greenhouse SW; Califf RM; Ross AM
    J Am Coll Cardiol; 1996 Aug; 28(2):331-7. PubMed ID: 8800106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial.
    Brochier ML
    Eur Heart J; 1993 Jul; 14(7):951-7. PubMed ID: 8375421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized trial of thrombolysis versus heparin in unstable angina.
    Schreiber TL; Rizik D; White C; Sharma GV; Cowley M; Macina G; Reddy PS; Kantounis L; Timmis GC; Margulis A
    Circulation; 1992 Nov; 86(5):1407-14. PubMed ID: 1423953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction.
    Schreiber TL; Miller DH; Silvasi D; McNulty A; Zola BE
    Am Heart J; 1990 Jun; 119(6):1238-44. PubMed ID: 2353611
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
    Wallentin L; Bergstrand L; Dellborg M; Fellenius C; Granger CB; Lindahl B; Lins LE; Nilsson T; Pehrsson K; Siegbahn A; Swahn E
    Eur Heart J; 2003 May; 24(10):897-908. PubMed ID: 12714021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current concepts in coronary thrombolysis.
    Eisenberg PR
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1161-70. PubMed ID: 1400079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
    Sakamoto T; Ogawa H; Yasue H; Oda Y; Kitajima S; Tsumoto K; Mizokami H
    Circulation; 1994 Jul; 90(1):427-32. PubMed ID: 8026029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence, consequences, and risk factors of early reocclusion after primary and/or rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction.
    Garot P; Himbert D; Juliard JM; Golmard JL; Steg PG
    Am J Cardiol; 1998 Sep; 82(5):554-8. PubMed ID: 9732878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction.
    Ward SR; Sutton JM; Pieper KS; Schwaiger M; Califf RM; Topol EJ
    Am J Cardiol; 1997 Mar; 79(5):539-44. PubMed ID: 9068505
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial).
    Nikolsky E; Mehran R; Dangas GD; Yu J; Parise H; Xu K; Pocock SJ; Stone GW
    Am J Cardiol; 2012 Mar; 109(6):831-8. PubMed ID: 22196778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.